Do fair and just systems require compensation for the disadvantages of the natural lottery? a discussion on society's duties on the provision of gene therapy

Author:

Ekmekci PE1,Güner MD2

Affiliation:

1. Department of History of Medicine and Ethics, TOBB Economics and Technology University Medical School , Ankara , Turkey

2. Department of Medical Pharmacology, TOBB Economics and Technology University Medical School , Ankara , Turkey

Abstract

Abstract Genetic diseases have been thought to be acquired as a result of sheer bad luck. However, recent advances in medical science have demonstrated the mechanisms of genetic disorders, which enable us to intervene with their occurrence and treatment. Today, gene therapy, once considered too risky, has become safer and can save the lives of patients with previously untreatable and lethal genetic diseases. However, the positive expectations from gene therapy are overshadowed by their extremely high prices. Thus, the duty of society in the provision of gene therapies has been frequently discussed. The discussions mainly focus on how to meet the genetic treatment needs of patients without violating the notion of justice and fairness in society. This study discusses the theoretical grounds for society's duty to compensate for genetic disease patients' disadvantages by providing them with appropriate genetic treatment. The main question is whether a fair and just system requires society to provide available lifesaving gene therapy to patients in need. The discussion is constructed on the crucial notion of the fair equal opportunity principle in a just system and the plausibility of including disadvantages emerging from bad luck in the natural lottery in the domain of justice.

Publisher

Walter de Gruyter GmbH

Subject

Genetics (clinical),Genetics

Reference15 articles.

1. Glybera EPAR summary for public https://www.ema.europa.eu/en/medicines/human/EPAR/glybera)

2. Strimvelis EPAR summary for public https://www.ema.europa.eu/en/medicines/human/EPAR/strimvelis)

3. Aiuti A, Roncarolo MG, Naldini L. Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: Paving the road for the next generation of advanced therapy medicinal products. EMBO Mol Med. 2017; 9(6): 737-740.10.15252/emmm.20170757328396566

4. Food and Drug Administration. Approval History, Letters, Reviews, and Related Documents. IMLYGIC. 2015 https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm 469411.htm).

5. Food and Drug Administration. Approval History, Letters, Reviews and Related Documents. KYM-RIAH. 2017 https://www.fda.gov/Biologics Blood Vaccines/ CellularGeneTherapyProducts/Approved-Products/ ucm573706.htm).

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3